Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209467 | 0.91 | HTR1A (0.30) | — | |
| SCHEMBL13400892 | 0.89 | TUBB4A (0.32) | — | |
| SCHEMBL8214177 | 0.84 | L3MBTL1 (0.35) | SMN1; SMN2CNR1CNR2L3MBTL1LMNA | |
| SCHEMBL13434838 | 0.82 | — | — | |
| SCHEMBL18281574 | 0.82 | L3MBTL1 (0.37) | SMN1; SMN2ALOX15TSHRHSD17B10L3MBTL1 | |
| SCHEMBL796662 | 0.82 | L3MBTL1 (0.37) | SMN1; SMN2ALOX15TSHRHSD17B10L3MBTL1 | |
| SCHEMBL13434827 | 0.79 | ALDH1A1 (0.32) | SMN1; SMN2LMNAALDH1A1KDM4EHTT | |
| SCHEMBL13448827 | 0.79 | POLB (0.41) | SMN1; SMN2ALOX15TSHRHSD17B10L3MBTL1 | |
| SCHEMBL16232209 | 0.77 | RARB (0.38) | SMN1; SMN2ALOX15TSHRHSD17B10L3MBTL1 | |
| SCHEMBL13400875 | 0.77 | MAPT (0.40) | SMN1; SMN2TSHRL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404216-B2 | Dendritic chelated compounds, methods for making the same and pharmaceutical compositions containing the same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404216-B2 | Dendritic chelated compounds, methods for making the same and pharmaceutical compositions containing the same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100104512-A1 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100104512-A1 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-04-29 | — | — | US | disclosed |
| WO-2008043911-A2 | DENDRITIC CHELATED COMPOUNDS, METHODS FOR MAKING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104512-A1 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | ZYX, CXCR4, ZFX | SMN1; SMN2 4668/4885ALOX15 2789/4885TSHR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.